World Health Organisation SAGE recommends use of Novavax Covid-19 vaccine as booster
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
The company has started manufacturing the Sputnik Light vaccine
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
Effectiveness of Covaxin against the Omicron variant is currently being studied
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
The company will donate 5000 nebulizers to primary health care centres in rural India
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Subscribe To Our Newsletter & Stay Updated